Hokkaido University Collection of Scholarly and Academic Papers >
Hokkaido University Hospital >
Peer-reviewed Journal Articles, etc >
Do DPP-4 inhibitors improve endotherial cell function?
This item is licensed under:Creative Commons Attribution 4.0 International
Title: | Do DPP-4 inhibitors improve endotherial cell function? |
Authors: | Nomoto, Hiroshi Browse this author | Miyoshi, Hideaki Browse this author →KAKEN DB | Nakamura, Akinobu Browse this author →KAKEN DB | Atsumi, Tatsuya Browse this author →KAKEN DB | Manda, Naoki Browse this author | Kurihara, Yoshio Browse this author | Aoki, Shin Browse this author |
Keywords: | DPP-4 inhibitor | Endothelial cell function |
Issue Date: | 2017 |
Publisher: | Allied Academies |
Journal Title: | Current Trends in Cardiology |
Volume: | 1 |
Issue: | 1 |
Start Page: | 12 |
End Page: | 14 |
Abstract: | DPP-4 inhibitors have been used to treat patients with type 2 diabetes mellitus. These agents not only provide glycemic control, but also have other favorable effects, including the prevention of atherosclerosis. However, it has not been determined whether these agents can improve or maintain endothelial cell function. We previously reported the results of two prospective studies assessing the effects of incretin agents on flow-mediated dilation in patients with type 2 diabetes mellitus without severe atherosclerotic diseases. These studies showed that both the DPP-4 inhibitor sitagliptin and the GLP-1 analogue liraglutide did not improve endothelial cell function. This report discusses the effects of sitagliptin on early-stage atherosclerosis and beta-cell function. |
Rights: | http://creativecommons.org/licenses/by/4.0/ |
Type: | article |
URI: | http://hdl.handle.net/2115/67261 |
Appears in Collections: | 北海道大学病院 (Hokkaido University Hospital) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)
|
Submitter: 三好 秀明
|